Carlos Jerjes‐Sánchez, Alicia Ramírez‐Rivera, Nayeli Zayas Hernandez, Guillermo Cueto Robledo, Humberto García‐Aguilar, Pedro Gutiérrez‐Fajardo, Mario Seoane García de León, Francisco Moreno Hoyos‐Abril, Miguel Ernesto Beltrán Gámez, Jose Elizalde, Tomás Pulido Fccp, Julio Sandoval, The REMEHIP Investigators
Escuela de Medicina y Ciencias de la Salud Monterey. TecSalud San Pedro Garza Garcia. Unidad de Investigación Clínica en Medicina S.C. Monterrey. Instituto Nacional de Cardiología Ignacio Chavez. Hospital General de México. Centro Médico Nacional 20 de noviembre. Cardiotest. Centro Médico ABC. Hospital Universitario “Dr. José E. González” UANL Monterrey. Hospital Angeles de Tijuana. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
Mexico
Pulmonary Circulation
Pulm Circ 2024; 14:
DOI: 10.1002/pul2.12395
Abstract
Data on demographic characteristics and therapeutic approaches in Latin American pulmonary arterial hypertension (PAH) patients are scarce. Pulmonary Hypertension Mexican registry (REMEHIP) is a multicenter Mexican registry of adult and pediatric patients, including prevalent and incident cases. Objective: assess clinical characteristics, treatment trends, and in-hospital outcomes. Inclusion: age >2 years, diagnosis of pulmonary hypertension (PH) (groups 1 and 4), right heart catheterization with mPAP ≥25 mmHg, PWP ≤ 15 mmHg, and PVR > 3 Wood unit (WU). We included 875 PH patients, 619 adults, 133 pediatric idiopathic PAH (IPAH), and 123 chronic thromboembolic pulmonary hypertension (CTEPH) patients. We enrolled 48.4% of the incident and 51.6% of the prevalent adult and pediatric patients. PAH adults: age 43 ± 15, females 81.9%, functional class (FC) (I/II) 66.5%, 6-min walk distance (6MWD) 378 ± 112 m, mPAP 57.3 ± 19.0 mmHg, confidence interval (CI) 3.3 ± 1.5 L/min/m2, PVR 12.0 ± 8.1 WU. PAH pediatrics: age 9 ± 5, females 51.1%, FC (I/II) 85.5%, 6MWD 376 ± 103 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m2, PVR 16.4 ± 13.5 WU. CTEPH: age 44 ± 17, females 56.1%, FC (I/II) 65.5%, 6MWD 369 ± 126 m, mPAP 49.7 ± 13.4 mmHg, CI 2.6 ± 0.9 L/min/m2, PVR 10.5 + 6.5 WU. When we analyzed the IPAH group separately, it sustained a high functional class I/II incidence. REMEHIP shows better functional class in young females with severe PAH than in American and European patients. Also, PAH pediatric patients had a better functional class than other registries. However, our registry also shows that our population’s access to specific pharmacologic treatments is still far from optimal.
Category
Symptoms and Findings Associated with Pulmonary Vascular Disease
Diagnostic Testing for Pulmonary Vascular Disease. Non-invasive Testing
Diagnostic Testing for Pulmonary Vascular Disease. Invasive Testing
Age Focus: Pediatric Pulmonary Vascular Disease or Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes